ArticleEuropean journal of medical research2025
Prognostic risk model of six m7 g-related lncRNAs in lung adenocarcinoma.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLung cancer is the most widespread and fatal oncological disease, with lung adenocarcinoma (LUAD) being the predominant subtype, characterized by a poor long-term survival rate. Although the N7-methylguanosone (m7G) genes have been reported to be correlated with the prognosis of lung cancer, m7G gene-associated Long non-coding RNA (lncRNAs) have been poorly studied in LUAD. This study aimed to explore the prognostic value of an m7G-related lncRNAs model in LUAD.
methodsTranscriptome and clinical data of LUAD patients were downloaded from the TCGA database. Pearson correlation analysis and Cox regression analysis were utilized to identify lncRNAs associated with m7G-related genes and prognosis. Then m7G-related prognostic model was constructed by LASSO regression analysis, with its accuracy and independence were validated by AUC curve, survival analysis and COX regression, respectively. Subsequently, a nomogram, KEGG analysis, GO analysis and immune infiltration analysis were applied successively to reveal potential prognosis of LUAD patients based on prognostic model. Finally, expression level of hub lncRNAs in the mode was detected by RT-qPCR, and the correlation analysis revealed the relationship between hub lncRNAs and clinical information of LUAD patients.
resultsThe m7G-related lncRNA prognosis model for LUAD, consisting of 6 lncRNAs, stratified patients into high- and low- risk groups. High-risk patients were associated with poor prognosis, and the model's accuracy was confirmed by ROC curves, with the AUC of all-year approaching 0.737. Expression of AC007128.1 and HNRNPUP1 were higher in tumor tissues compared to normal tissue, while the other lncRNAs showed the opposite state, supporting the model's signature. Immune infiltration analysis indicated that patients in the low-risk group were closely related to better immune cell infiltration and more highly expressed immune checkpoint genes.
conclusionsThe prognosis model of six m7G-related lncRNAs can accurately predict the OS of LUAD patients and provide valuable insights for treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.